Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors.

Anita K Nivedha, Christofer S Tautermann, Supriyo Bhattacharya, Sangbae Lee, Paola Casarosa, Ines Kollak, Tobias Kiechle, Nagarajan Vaidehi

Journal: Molecular pharmacology 2019;93(4):288-296

PMID: 29367258

Abstract

G-protein-coupled receptors (GPCRs) mediate multiple signaling pathways in the cell, depending on the agonist that activates the receptor and multiple cellular factors. Agonists that show higher potency to specific signaling pathways over others are known as "biased agonists" and have been shown to have better therapeutic index. Although biased agonists are desirable, their design poses several challenges to date. The number of assays to identify biased agonists seems expensive and tedious. Therefore, computational methods that can reliably calculate the possible bias of various ligands ahead of experiments and provide guidance, will be both cost and time effective. In this work, using the mechanism of allosteric communication from the extracellular region to the intracellular transducer protein coupling region in GPCRs, we have developed a computational method to calculate ligand bias ahead of experiments. We have validated the method for several -arrestin-biased agonists in -adrenergic receptor (2AR), serotonin receptors 5-HT1B and 5-HT2B and for G-protein-biased agonists in the -opioid receptor. Using this computational method, we also performed a blind prediction followed by experimental testing and showed that the agonist carmoterol is -arrestin-biased in 2AR. Additionally, we have identified amino acid residues in the biased agonist binding site in both 2AR and -opioid receptors that are involved in potentiating the ligand bias. We call these residues functional hotspots, and they can be used to derive pharmacophores to design biased agonists in GPCRs.

Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Address: Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.).; Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.) [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.